1. Patología y Estudios Moleculares en el Cáncer de Pulmón de Células no Pequeñas (CPCNP): 2do consenso nacional de la sociedad panameña de oncología (SPO).
- Author
-
Vergara, R., Barrera, I., González, K., and Crismatt, A.
- Abstract
In the last decade, histopathological diagnosis has become an important determinant for the treatment of non-small cell lung cancer (NSCLC). A growing number of patients benefit from therapies targeting particular molecular alterations (Mutations, Fusion genes... etc.), thus accurate diagnosis and laboratory tests based on predictive biomarkers for the determination of patients who more likely to respond to target therapies, represent a change in the diagnostic paradigm of lung cancer and are now a standard[1]. The histopathological diagnosis of lung cancer is a multi-step process that begins with the morphological diagnosis to determine the histological type (refined by immunohistochemistry in the required cases), followed by the molecular characterization of the tumor. The increasing complexity of the diagnostic algorithm represents new challenges for patients with lung cancer, in which the availability of sufficient tissue for the realization of all molecular tests stands out. Most NSCLC are diagnosed in advanced stages of the disease, so large tumor samples (surgical resection) are obtained only in a few cases. Therefore, it is imperative that any acquisition of tumor tissue is maximized to achieve the required molecular tests. The role of the multidisciplinary team that includes the pulmonologist, radiologist, pathologist, thoracic surgeon and oncologist is essential to determine the best approach for each patient[2,3]. [ABSTRACT FROM AUTHOR]
- Published
- 2017